- Home
- SUPN vs OPEN Comparison
SUPN vs OPEN Comparison
Compare SUPN & OPEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- OPEN
- Stock Information
- Founded
- SUPN 2005
- OPEN 2014
- Country
- SUPN United States
- OPEN United States
- Employees
- SUPN N/A
- OPEN N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- OPEN Real Estate
- Sector
- SUPN Health Care
- OPEN Finance
- Exchange
- SUPN Nasdaq
- OPEN Nasdaq
- Market Cap
- SUPN 1.9B
- OPEN N/A
- IPO Year
- SUPN 2012
- OPEN N/A
- Fundamental
- Price
- SUPN $33.84
- OPEN $1.82
- Analyst Decision
- SUPN Hold
- OPEN Hold
- Analyst Count
- SUPN 1
- OPEN 6
- Target Price
- SUPN $36.00
- OPEN $2.77
- AVG Volume (30 Days)
- SUPN 334.5K
- OPEN 32.3M
- Earning Date
- SUPN 11-06-2024
- OPEN 11-07-2024
- Dividend Yield
- SUPN N/A
- OPEN N/A
- EPS Growth
- SUPN N/A
- OPEN N/A
- EPS
- SUPN 0.08
- OPEN N/A
- Revenue
- SUPN $630,163,000.00
- OPEN $4,542,000,000.00
- Revenue This Year
- SUPN $4.01
- OPEN N/A
- Revenue Next Year
- SUPN $0.10
- OPEN $42.12
- P/E Ratio
- SUPN $447.14
- OPEN N/A
- Revenue Growth
- SUPN N/A
- OPEN N/A
- 52 Week Low
- SUPN $21.99
- OPEN $1.58
- 52 Week High
- SUPN $35.44
- OPEN $4.89
- Technical
- Relative Strength Index (RSI)
- SUPN 63.14
- OPEN 43.30
- Support Level
- SUPN $31.63
- OPEN $1.71
- Resistance Level
- SUPN $34.21
- OPEN $1.97
- Average True Range (ATR)
- SUPN 0.85
- OPEN 0.12
- MACD
- SUPN 0.28
- OPEN -0.00
- Stochastic Oscillator
- SUPN 89.09
- OPEN 27.50
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.